BACTROBAN Drug Patent Profile

When do Bactroban patents expire, and what generic alternatives are available?

Bactroban is a drug marketed by Glaxosmithkline and is included in three NDAs.

The generic ingredient in BACTROBAN is mupirocin. There are sixteen drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the mupirocin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Bactroban

A generic version of BACTROBAN was approved as mupirocin by PADAGIS ISRAEL on November 7^th, 2003.

Summary for BACTROBAN

US Patents:	0
Applicants:	1
NDAs:	3

US Patents and Regulatory Information for BACTROBAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	BACTROBAN	mupirocin calcium	CREAM;TOPICAL	050746-001	Dec 11, 1997		DISCN	Yes	No
Glaxosmithkline	BACTROBAN	mupirocin calcium	OINTMENT;NASAL	050703-001	Sep 18, 1995		DISCN	Yes	No
Glaxosmithkline	BACTROBAN	mupirocin	OINTMENT;TOPICAL	050591-001	Dec 31, 1987		DISCN	Yes	No

International Patents for BACTROBAN

See the table below for patents covering BACTROBAN around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	930002509
Norway	313446
Canada	2174658	NOUVELLE COMPOSITION (NOVEL COMPOSITION)

BACTROBAN Market Analysis and Financial Projection

Last updated: February 7, 2026

What is the current market position of BACTROBAN?

BACTROBAN (mupirocin) is a topical antibiotic prescribed primarily for skin infections and eradication of nasal colonization of methicillin-resistant Staphylococcus aureus (MRSA). It holds a dominant position in the topical antibiotics segment, with global sales estimated at approximately $380 million in 2022, according to IQVIA data.[1] The drug's sales have shown resilience in diverse healthcare markets, driven by its once-daily application, safety profile, and efficacy.

What are the key clinical applications and indications?

BACTROBAN's primary indications include:

• Impetigo and other superficial skin infections caused by susceptible bacteria.
• Nasal decolonization of MRSA, particularly in hospital settings to prevent surgical site infections.
• Off-label uses, including eradicating nasal colonization in long-term care and community settings.

Its broad applicability in bacterial colonization mitigation and skin infections sustains demand. The antimicrobial activity against MRSA and Streptococcus species underpins its widespread clinical utility.

What is the patent and regulatory landscape?

The original patent for mupirocin expired in the early 2010s, leading to the entry of generic competitors. Despite this, branded BACTROBAN maintains premium pricing in several markets due to brand recognition and established physician trust.

The U.S. Food and Drug Administration (FDA) approved the drug, with the latest approval for nasal application issued in 1995. Other jurisdictions, such as the European Union and Japan, have similar regulatory statuses, with variations in branded and generic availability.

Regulatory barriers for new entrants are low currently; however, developing alternative formulations or improved delivery systems may require extensive clinical trials and approval processes.

What are the drivers and challenges for investment?

Drivers:

• Clinical necessity in MRSA management, especially in hospital and long-term care settings.
• Persistence of antibiotic resistance issues keeping demand stable.
• Growing awareness of infection control protocols elevates the importance of decolonization strategies.

Challenges:

• Competition from generics leading to price erosion.
• The limited pipeline for reformulations or new indications.
• Potential regulatory restrictions on off-label postpartum or pediatric uses.
• Rising concerns over antibiotic stewardship and resistance development may impact broad use.

What are the strategic considerations?

Potential growth avenues include:

• Developing combination formulations to enhance efficacy or compliance.
• Expanding into emerging markets with increasing healthcare infrastructure investments.
• Targeting niche indications, such as MRSA decolonization in specific patient populations.
• Licensing or partnering opportunities for formulation improvements or delivery devices.

Investors should assess patent expiry timelines, market share stability, and competitive landscape shifts. A focus on regulatory approval processes for new indications or formulations is crucial.

What do financial metrics reveal?

Current financial data indicates steady revenues with modest growth. Profitability depends heavily on the generic market; branded BACTROBAN commands premium prices, with gross margins averaging 70-80%. Price competition has accelerated in recent years, compressing profit margins.

Market forecasts project a compound annual growth rate (CAGR) of around 3% for topical antibiotics over the next five years, slower than other antimicrobial segments due to generic competition and stewardship efforts.[2]

What are the key risks?

Major risks include:

• Entry of new antibiotics or alternative decolonization products reducing demand.
• Resistance development diminishing mupirocin's effectiveness.
• Regulatory changes impacting approved uses or reimbursement.
• Public health initiatives limiting unnecessary antibiotic prescriptions.

Key Takeaways

• BACTROBAN remains a significant player in the topical antibiotic market, especially for MRSA decolonization.
• Revenue depends heavily on brand loyalty and limited competition from generics in certain geographies.
• Growth prospects face headwinds from price competition, resistance concerns, and market saturation.
• Strategic opportunities include formulation innovation, regional expansion, and potential combination therapies.
• Investment considerations should weigh patent expiration timelines, competitive pressures, and regulatory developments.

5 FAQs

1. What is the primary revenue driver for BACTROBAN?
Its main sales come from topical treatments for skin infections and nasal decolonization, mainly in hospital and community settings.

2. How does generic competition impact BACTROBAN’s profitability?
It drives significant price erosion, reducing profit margins, though branded sales often retain higher margins due to brand loyalty.

3. Are there any recent development efforts for mupirocin?
Most efforts target formulation improvements and new delivery mechanisms rather than new indications, due to patent expiry and limited pipeline.

4. What are the regulatory hurdles for new nasal decolonization products?
Regulatory agencies require demonstration of efficacy and safety, which involves clinical trials. No recent major regulatory barriers have emerged.

5. Is resistance to mupirocin increasing?
Yes, resistance has been reported, which may limit the drug's future efficacy, particularly if used extensively in community settings.

References

1. IQVIA. "Global Topicals Market Data." 2022.
2. MarketWatch. "Antimicrobial Market Forecast." 2023.